Loading clinical trials...
Loading clinical trials...
A Randomised, Double-blind, Dose-finding, Multicenter Study of the Safety, Tolerability, and Efficacy of GSK2251052 Therapy Compared to Imipenem-cilastatin in the Treatment of Adult Subjects With Febrile Complicated Lower Urinary Tract Infections and Acute Pyelonephritis
Conditions
Interventions
GSK2251052
imipenem-cilastatin
+1 more
Locations
24
United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Council Bluffs, Iowa, United States
GSK Investigational Site
Topeka, Kansas, United States
GSK Investigational Site
Corsicana, Texas, United States
GSK Investigational Site
Chicoutimi, Quebec, Canada
GSK Investigational Site
Sherbrooke, Quebec, Canada
Start Date
June 28, 2011
Primary Completion Date
March 6, 2012
Completion Date
March 6, 2012
Last Updated
September 8, 2017
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions